- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Esaote enters Japanese MR market with local distributor agreement
Expansion follows pattern of growth elsewhereItalian medical instrumentation company Esaote has secured a deal to sell its MR scanners in Japan. The low-cost MRI machines, dedicated to extremity imaging, will be available to
Expansion follows pattern of growth elsewhere
Italian medical instrumentation company Esaote has secured a deal to sell its MR scanners in Japan. The low-cost MRI machines, dedicated to extremity imaging, will be available to Japanese customers through a local distributor from Jan. 1, 2003. Esaote received confirmation of the agreement just prior to the RSNA meeting.
Esaote's MRI portfolio currently comprises two open-style scanners: the E-Scan XQ and the C-Scan. Both offer imaging at 0.2T, with radio-frequency receiving coils tailored to musculoskeletal joints. About 950 systems have been sold over the past decade to hospitals, private clinics, and sports medicine centers.
The Japanese launch underscores Esaote's increasing commitment to Asian markets and its policy of working with local distributors. Prior to 2001, Esaote's MR scanners were available only in the U.S. and Western Europe. Sales channels have now opened in Mexico and Korea, again via local third parties.
The scanners are sold in Brazil through GE Medical Systems. In China, one of Esaote's subsidiary companies handles MRI equipment sales.
India may be the next country added to the distribution list, given the price-oriented nature of the country's medical imaging market, according to Massimo Guerra, area manager for Esaote's MRI division. E-Scan systems sell for about half the price of standard low-field MR scanners. But Esaote will first have to find a good partner in India.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
